Abstract：Objective: To study the clinical efficacy of saccharomyces boulardii in the treatment of children with acute infectious diarrhea (AID), and to evaluate its effects on symptom improvement and serum inflammatory factors. Methods: 160 children patients with AID treated in our hospital from April 2017 to April 2019 were selected for the study, and the patients were divided into observation group (odd medical record numbers) and control group (even medical record numbers) using a odd-even number method, with 80 cases in each group. On the basis of routine measures, control group was administrated montmorillonite powder, and observation group was administrated saccharomyces boulardii combined with montmorillonite powder, and they were treated for one week. The effective rate of treatment, symptom improvement, stool frequency traits, intestinal microbial condition, levels of serum inflammatory indexes [interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), hypersensitive C-reactive protein (hs-CRP), interferon-γ (INF-γ)] and occurrence of adverse reactions were compared between the two groups. Results: The effective rate of treatment in observation group was significantly higher than that in control group (92.50% vs 80.00%) (P<0.05). The disappearance times of abdominal pain, vomiting and diarrhea and hospital stay in observation group were significantly lower than those in control group (P<0.05). After treatment, the stool frequency, stool trait score, and levels of IL-6, TNF-α, hs-CRP and INF-γ in the two groups were significantly decreased compared with those before treatment, while the quantity of bacteroides was significantly increased (P<0.05), and the above indexes in observation group were significantly different from those in control group at the same time point (P<0.05). There was no significant difference in incidence rate of adverse reactions between the two groups during treatment (P>0.05). Conclusion: Saccharomyces boulardii has significant clinical efficacy in the treatment of acute infectious diarrhea, and it can effectively improve the symptoms, and reduce the inflammatory response, with good safety and good clinical application value.
2021, Vol. 27 
冀公网安备13080202000677号